An Information Portal to 112722 Biological Macromolecular Structures

CEL is found in 4 entries
  •   Chemical Component Summary   Hide
    Identifiers 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
    Synonyms CELECOXIB
    Formula C17 H14 F3 N3 O2 S
    Molecular Weight 381.37 g/mol
    Type non-polymer
    Isomeric SMILES
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00482   (Stereoisomeric match)
    Name Celecoxib
    • approved
    • investigational
    Description Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form.
    • Celebrex
    • Celecoxib
    • Célécoxib
    • Celecoxibum
    • P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
    Brand names
    • Celebrex
    • Celecoxib
    • Articox
    • Articoxib
    • Artiflex
    • Artilog
    • Artix
    • Artrixib
    • Blockten
    • Caditar
    • Cefinix
    • Celact
    • Celebra
    • Onsenal
    • Valdyne
    Affected organism Humans and other mammals
    Indication For relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis
    Pharmacology Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Celecoxib is used to treat rheumatoid arthritis, osteoarthritis, and familial adenomatous polyposis (FAP). Because of its lack of platelet effects, celecoxib is not a substitute for aspirin for cardiovascular prophylaxis. It is not known if there are any effects of celecoxib on platelets that may contribute to the increased risk of serious cardiovascular thrombotic adverse events associated with the use of celecoxib. Inhibition of PGE2 synthesis may lead to sodium and water retention through increased fluid reabsorption in the renal medullary thick ascending loop of Henle and perhaps other segments of the distal nephron. In the collecting ducts, PGE2 appears to inhibit water reabsorption by counteracting the action of antidiuretic hormone.
    Mechanism of action The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis. Unlike most NSAIDs, which inhibit both types of cyclooxygenases (COX-1 and COX-2), celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme. It binds with its polar sulfonamide side chain to a hydrophilic side pocket region close to the active COX-2 binding site. Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane.
    Route of administration oral
    • L01XX33
    • M01AH01
    AHFS-Code 28:08.04.08
    CAS number 169590-42-5
    Name Sequence search Pharmacological action Actions
    Prostaglandin G/H synthase 2   Search  yes inhibitor
    3-phosphoinositide-dependent protein kinase 1   Search  unknown inhibitor
Ligand Image